NITRO-OXIDATIVE STRESS, VEGF AND MMP-9 IN PATIENTS WITH CIRRHOTIC AND NON-CIRRHOTIC PORTAL HYPERTENSION

LEON ADRIAN MUTI¹, ALINA ELENA PÂRVU², ALEXANDRA M. CRĂCIUN³, NICOLAE MIRON¹, MONICA ACALOVSCHI¹

¹3rd Medical Clinic, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
²Pathophysiology Department, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
³Biochemistry Department, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

Background and aims. Nitro-oxidative stress may have pathophysiological consequences. The study aimed to assess the nitro-oxidative stress, the vascular growth factor, and metalloproteinase-9 levels in patients with noncirrhotic and cirrhotic portal hypertension.

Methods. Patients with noncirrhotic portal hypertension (n=50) and cirrhotic portal hypertension (n=50) from the 3rd Medical Clinic in Cluj-Napoca Romania were prospectively enrolled between October 2004 and October 2006. A control group of healthy volunteers (n=50) was also evaluated. Nitro-oxidative stress was assessed by measuring serum concentration of nitrates and nitrite, 3-nitrotyrosine, total oxidative status, total antioxidant reactivity, and oxidative stress index. Serum vascular growth factor and matrix metalloproteinase-9 were also determined.

Results. Serum nitrites and nitrate levels significantly increased in both noncirrhotic (p<0.001) and cirrhotic portal hypertension (p=0.057). 3-nitrotyrosine also increased in noncirrhotic (p=0.001) and cirrhotic portal hypertension patients (p=0.014). Total oxidative status showed a significant increase in noncirrhotic (p<0.001) and in cirrhotic portal hypertension (p<0.001), but total antioxidant reactivity did not change significantly. The oxidative stress index increased in both noncirrhotic (p<0.001) and cirrhotic portal hypertension (p<0.001), as well as the serum vascular growth factor (p=0.005 and p=0.01, respectively). In NCPHT patients serum MMP-9 was significantly lower than in the healthy controls (p=0.03) and CPHT patients (p=0.05).

Conclusion. In patients with noncirrhotic and cirrhotic portal hypertension a significant systemic nitro-oxidative stress was found, correlated with an increase of VEGF. MMP-9 decreased in noncirrhotic portal hypertension.

Keywords: nitro-oxidative stress, vascular endothelial growth factor, matrix metalloproteinase-9, non-cirrhotic portal hypertension, cirrhotic portal hypertension.
PHT (NCPHT) hepatic venous pressure gradient is normal or only mildly elevated. Some NCPHT diseases progress without any sign of significant liver dysfunction [2,3]. The diseases leading to NCPH are primarily vascular in nature, and frequently PHT is a late manifestation of the primary disease [3]. After PHT develops, it affects extrahepatic vessels from the splanchic and systemic circulation, by inducing arterial vasodilatation and collateral vessel formation [4,5]. The increase in blood flow leads to a hyperdynamic splanchic and systemic circulatory state. The mechanisms underlying this phenomenon are not fully understood [6]. An overproduction of nitric oxide (NO) in the splanchic and systemic circulation seems to be the most important mechanism. NO is synthesized by nitric oxide synthase (NOS). There are four isoforms of NOS: endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), neuronal nitric oxide synthase (nNOS) and mitochondrial nitric oxide synthase [7].

Three sources of excessive NO synthesis were identified in PHT. The first source is eNOS induced NO synthesis. An eNOS up-regulation was found in the superior mesenteric arteries endotelium even before the development of the hyperdynamic splanchic circulation [5]. The second source is iNOS-induced NO synthesis. In cirrhosis, due to the intrahepatic blood flow obstruction, liver LPS detoxification is reduced leading to plasma LPS increase. Resident macrophages from the the splanchic circulation are activated by this circulating LPS and secrete proinflammatory cytokines, which then stimulate iNOS expression in extrahepatic vasculature [5,8]. The third source is nNOS induced NO synthesis. Perivascular nNOS-containing nerves mediate neurogenic vasodilation by releasing NO. Up-regulation of nNOS has been recently demonstrated in experimental rats PHT as an additional pathway for mesenteric smooth muscle relaxation [7,9].

It has been established that collateral vessels formation is stimulated by angiogenic factors, such as vascular endothelial growth factor (VEGF) and that favours PHT progression [10]. At the same time VEGF stimulates NO synthesis by inducing eNOS protein expression and activity [11]. Other studies also reported that NO-mediated angiogenesis was due to endotelial VEGF, creating a vicious cycle between vasodilatation and angiogenesis [7]. Active matrix metaloproteinases (MMP) are also important mediators of inflammation and angiogenesis [12].

No information was available on the possible correlations between the NO synthesis, VEGF and MMP-9 in NCPHT. Therefore, the present study was undertaken to test the hypothesis that systemic release of NO may induce nitro-oxidative stress that influences VEGF and MMP-9 in NCPHT patients. We also aimed to find out if there were significant differences between NCPHT and CPHT regarding systemic nitro-oxidative stress, VEGF and MMP-9 levels.

Materials and methods

Study population

The present prospective study included 210 consecutive patients with NCPHT (n=105) and CPHT (n=105) admitted to the 3rd Medical Clinic in Cluj-Napoca, Romania between October 2004 and October 2006, only 50 having NCPHT and 50 with CPHT. The enrolled patients met the inclusion criteria regarding presence of PHT as demonstrated by evidence of porto-systemic vascular derivations (ultrasound or endoscopy) and/or complete obstruction in the portal venous system (ultrasound and/or CT scan) and/or reversed blood flow in the portal vein (Doppler ultrasound). The inclusion criteria for the CPHT group were the presence of cirrhosis diagnosed by liver biopsy, the macroscopic aspect of the liver during surgical intervention and the ultrasound aspect of the liver. In the NCPHT group liver cirrhosis was excluded using the same criteria [13]. All patients were over 18 years old, none of them had ascites or took any medication known to affect blood flow or vascular tonus. The two PHT groups were also compared to a control group of healthy volunteers (n=50). Written informed consent was obtained from all patients prior to the study. The study protocol was reviewed and approved by the Ethics Committee of University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca, Romania.

Laboratory analysis

Chemistry. The 3-nitrotyrosine (3NT) ELISA Kit (KA0445) was purchased from ABNOVA c/o EMBLEM (Heidelberg, Germany), MMP-9 (DMP900) and VEGF (DVE00) ELISA Kits were purchased from R&D Systems Europe (Bucharest, Romania), Sulphanilamide (SULF), N-(1-Naphthyl) ethylenediamine dihydrochloride (NEDD), vanadium (III) chloride (VCl3), methanol, diethylether, xylene orange [o-cresolsofphthalein-3,3-bis (sodium methyliminodiacetate), ortho diaminosidine dihydrochloride (3,3′-dimethoxybenzidine), ferrous ammonium sulphate, hydrogen peroxide (H2O2), sulphuric acid, hydroychloric acid, glyceral, trichloroacetic acid (TCA), and Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) were purchased from Merck (Darmstadt, Germany) and Sigma-Aldrich (Taufkirchen, Germany). Analytical grade chemicals were used exclusively.

Blood sampling. Fasting venous blood samples were taken into tubes and serum was separated after centrifugation at 1500 g for 10 minutes. Samples were stored until analysis at -80°C for biochemical tests and at -20°C for ELISA tests.

Nitric oxide synthesis evaluation. The Griess reaction was used as an indirect assay to determine the total serum nitrite (NO2–) and nitrate (NO3–) as an indirect marker of NO production (NOx) [14]. Serum samples were filtered through 10-kD filters (Sartorius AG, Goettingen, Germany) and contaminant proteins were precipitated by
extraction with a 3:1 (v:v) solution of methanol/diethyl ether. The sample methanol/diethyl ether ratio was 1:9 (v:v) [15]. In brief, in order to reduce nitrate to nitrite, 100 μL of supernatant was added to 100 μL of 8 mg/mL VCl₃, followed by the addition of the 100 μL Griess reagents (50 μL of SULF 2% and 50 μL of NEDD 0.1%). After 30 min incubation at 37°C, the sample absorbance was read at 540 nm. The nitrite levels were calculated by using sodium nitrite as a standard and expressed as nitrite μmol/L. Serum concentrations of protein-bound 3-nitrotyrosine (3NT) formed by the nitration of tyrosine-containing proteins was measured by commercially available ELISA kit, as a marker of nitro-oxidative stress. The results were expressed as 3NT μmol/L [16].

**Oxidative stress evaluation.** The total oxidative status (TOS) of the serum was measured using a colorimetric assay [17]. This assay evaluates the oxidation of ferrous ion to ferric ion in the presence of the reactive oxygen species in an acidic medium. The ferric ions are detected by reaction with xylene orange. Assay results were standardized using hydrogen peroxide (H₂O₂) as the oxidative species, and the assay results are expressed in μmol H₂O₂ Equiv/L. The total antioxidant response (TAR) was measured in serum using a colorimetric assay [18]. In this test the rate of hydroxyl radical production by the Fenton reaction was measured by monitoring the changes in the absorbance of coloured diansidyl radicals. After addition of a serum sample, the hydroxyl radical-initiated oxidative reactions are inhibited by antioxidant present in the serum sample. Inhibition of diansidyl oxidation prevents the subsequent colour change, thereby effectively evaluating the total antioxidant capacity of the serum. The test was calibrated using Trolox and results are expressed as mmol Trolox Equiv/L. The oxidative stress index (OSI) was found by calculating the ratio of the TOS to the TAR, according to the formula [19]:

\[
OSI = \frac{\text{TOS (μmol H₂O₂ Equiv/L)}}{\text{TAR (mmol Trolox Equiv/L)}}
\]

OSI represents a general indicator of the oxidative stress severity.

**VEGF and MMP-9 evaluation.** Serum concentrations of VEGF and MMP-9 were measured by commercially available ELISA kits. The results were expressed as VEGF pg/ml and MMP-9 ng/ml.

**Statistical analysis.** All results were expressed as the mean ± standard deviation (SD) whenever data were normally distributed. Otherwise the median and [Q1; Q3] were reported (Q1=first quartile; Q3=third quartile). Statistical comparisons between groups were performed using the one-way ANOVA tests with post hoc comparison by Tukey test. Pearson’s and Spearman’s correlation analysis were used to calculate statistical relationships between parameters. Values of P<0.05 were considered to be statistically significant. Analysis was performed using the SPSS 20.0 for Windows.

**Results**

**Demographic and etiologic data**

Subjects within the groups were matched regarding age or gender (Table I). Most of the patients included in the present study had prehepatic NCPHT (40% idiopathic portal vein thrombosis, 40% idiopathic portal vein cavernoma, 20% other). In the CPHT group, the etiology of liver cirrhosis was as follows: 30% had HBV, 30% HCV, 30% alcoholic cirrhosis, and 10% other etiologies.

**Nitric oxide synthesis evaluation**

Total serum NOx was significantly increased in the NCPHT patients (p<0.001) and in the CPHT patients (p=0.057) when compared to the control subjects. Furthermore, in the NCPHT group NO synthesis increased more than in the CPHT group (p=0.013). When evaluated

### Table I. Demographic data of the study groups.

|          | NCPHT       | CPHT        | CONTROL     |
|----------|-------------|-------------|-------------|
| Age (years) (mean±SE) | 42.6±2.20   | 49.2±1.83   | 40.3±1.60   |
| Total number of patients | 50          | 50          | 50          |
| Gender (M/F) | 27/23       | 24/26       | 25/25       |

Values are means ± SD. NCPHT, non-cirrhotic portal hypertension; CPHT, cirrhotic portal hypertension; M, male; F, female.

### Table II. Laboratory analysis results of the study groups.

|          | NCPHT       | CPHT        | CONTROL     |
|----------|-------------|-------------|-------------|
| NOx (nitrite μmol/L) | 32.26±1.70 | 28.48±2.70 | 21.57±1.98  |
| 3NT (3NT μmol/L)     | 361.04±54.95 | 281.30±18.23 | 169.95±14.48 |
| TOS (μmol H₂O₂ Equiv/L) | 177.29±3.95 | 128.55±5.67 | 24.15±2.49  |
| TAR (mmol Trolox Equiv/L) | 1.10±0.002 | 1.11±0.004 | 1.10±0.002  |
| OSI         | 16.009±0.36 | 11.65±0.52 | 2.17±0.22   |
| VEGF (pg/ml) | 620.67±115.88 | 440.41±109.83 | 223.85±41.10 |
| MMP-9 (ng/ml) | 2.0002±0.40 | 3.87±0.43 | 4.32±0.95   |

Values are means ± SD. NCPHT, non-cirrhotic portal hypertension; CPHT, cirrhotic portal hypertension; NOx, nitrates + nitrites; 3NT, 3 nitrotyrosine; TOS, total oxidative status; TAR, total antioxidant reactivity; OSI, oxidative stress index; VEGF, vascular endothelial growth factor; MMP-9, matrix metalloproteinase 9.
through 3NT, NO induced nitro-oxidative stress was significantly increased in both groups of patients, NCPHT (p=0.001) and CPHT (p=0.014). Furthermore, in NCPHT there was a higher elevation of 3NT than in CPHT (p=0.05) (Table II). 3NT values were correlated with NOx levels in both NCPHT (r=0.902) and CPHT patients (r=0.79).

**Oxidative stress evaluation**

Comparing the healthy subjects and the PHT patients it was found that TOS increased significantly in both PHT groups, respectively in NCPHT (p<0.001) and CPHT (p<0.001). There was a more important increase of TOS in the NCPHT than in CPHT (p<0.001) (Table II). NCPHT patients TOS correlated with NOx (r=0.69) and 3NT (r=0.84) levels. TAR determination did not find any significant changes in NCPHT (p=0.28) and CPHT (p=0.37) patients (Table II). OSI calculation showed a significant increase of the oxidative stress in all NCPHT (p<0.001) and CPHT (p<0.001) patients. In NCPHT group there was a more important increase of OSI than in CPHT group (p<0.001) (Table II). There was also a significant correlation between OSI and TOS in NCPHT (r=0.75) and CPHT (r=0.64) patients.

**VEGF and MMP-9 evaluation**

Serum VEGF was significantly increased in NCPHT (p=0.005) and in CPHT (p=0.01) groups. The difference between NCPHT and CPHT serum VEGF levels was small (p=0.041) (Table II). Moreover, in NCPHT and CPHT patients VEGF was correlated with NOx and 3NT. In NCPHT patients serum MMP-9 was significantly lower than in the healthy controls (p=0.03) and CPHT patients (p=0.05). CPHT group had a MMP-9 concentration comparable with than the controls (p=0.67) (Table II). In the NCPHT group serum MMP-9 concentration was negatively correlated with the OSI level (r=0.64).

**Discussion**

In this study, we focused on the evaluation of the systemic nitro-oxidative stress, MMP-9 and VEGF in NCPHT and CPHT patients. We found that in the NCPHT group there was a more important increase of the nitro-oxidative stress and VEGF synthesis than in CPHT group. MMP-9 was reduced only in the NCPHT group.

In the physiopathology of PHT the initiating step seems to be mesenteric splanchnic vasodilation. Previous studies have shown that splanchnic vasodilatation is induced by a complex multifactorial mechanism, which is not completely understood [4,5,20,21]. Until now three mechanisms have been identified: increase in local and systemic vasodilator levels, splanchnic vascular hyporesponsiveness to vasoconstrictors [4] and mesenteric sympathetic atrophy [22]. Among the arterial vasodilator mediators, nitric oxide (NO) has the most important role [23].

Nitrate (NO3-) and nitrite (NO2-) are end products of NO metabolism, that can be used as an indirect measure of the total NO concentration. By means of NOx assessment we found an important increase in NO synthesis in both NCPHT and CPHT patients. Our results were in agreement with previous reports that stated that in PHT hyperactive endothelial cells with increased eNOS activation play an important role in modulating the vascular changes from the splanchnic and systemic circulation [22]. Many factors that are increased in PHT, including shear stress, vasopressin, angiotensin II, and norepinephrine, can increase eNOS activity [24,25]. In PHT bacterial translocation from the gut into mesenteric lymph nodes is an early mechanism increasing TNFα and eNOS [25,26].

Previous studies demonstrated the involvement of iNOS in the hyperdynamic circulation of PHT [5]. In contrast to eNOS, iNOS expression is principally modulated by transcriptional factors. Among these is NF-κB, which can be activated by different stimuli including LPS, inflammatory cytokines and oxidative stress [7,27]. In PHT intestinal permeability is increased by the increased portal pressure, causing influx of gut flora-derived LPS [5,7]. iNOS produces almost hundred times more NO compared to eNOS [7]. Consistent with the current report was that NO synthesis increased more in NCPHT than in CPHT patients.

The ratio ROS/RNS plays an important physiological role in the cell, by regulating cell signalling, proliferation, differentiation and apoptosis. In the oxidative stress there is an imbalance between the formation of ROS and RSS, and the total antioxidant defending capacity of the cell [21,28]. Oxidative stress plays an important role in the pathogenesis of PHT because the association of overproduction of superoxide anions and NO observed in the model of partial portal vein ligation, peroxynitrite (ONOO−) formation occurs [23]. The amino acid tyrosine appears to be a particularly susceptible target for nitration by ONOO−, and the formation of free or protein-associated 3NT has received much recent interest as a potential biomarker for the generation of RNS in vivo [7]. Our results regarding 3NT further suggest that in NCPHT and CPHT there is a significant increase of the nitro-oxidative stress. In the present study, NOx, 3NT, TOS and OSI changes were closely correlated. Consequently, the data obtained indicate that in PHT there was concomitant increase of RNS and ROS, due excessive NO synthesis and high TOS formation. An important observation was also that in PHT patients there was no decrease of the TAR.

In PHT angiogenesis and vascular remodeling leads to the formation of portosystemic collateral circulation [22]. However, there is a significant increase in the production of intestinal VEGF with a subsequent increase in the expression of eNOS in the intestinal microcirculation [29]. Thus, increased intestinal VEGF levels may elevate portal hypertension by stimulating eNOS-derived NO production.
and by amplifying angiogenesis in the splanchnic circulation.

In experimental cirrhosis it was also found that plasma VEGF levels were significantly increased [30]. NO is also an angiogenic factor in PHT [25]. Consistent with the previous reports our results in NCPT and CPHT patients showed an important increase serum VEGF levels, with no difference related to the type of PHT. Moreover, VEGF was correlated with NOx and 3NT, sustaining the reciprocal influence between VEGF, NO synthesis and the nitro-oxidative stress.

Other studies showed different results. The differences were explained through the existence of VEGF isoforms and by the observation that in patients with liver disease, blood VEGF concentrations may change depending to the stage and etiology of the disease. Moreover, sample handling may also influence the measurement of blood VEGF concentration [30]. A limitation of the present study was that we considered an average without taking into account the disease etiology or stage.

Matrix remodeling occurs mainly due to the action of MMP [31,32]. These enzymes are secreted into the extracellular space as zymogens that require activation by a variety of stimuli. The active enzymes can be inhibited by the family of tissue inhibitors of metalloproteinases (TIMP) [33]. Activated macrophages produce NO and MMP-9 [34]. MMP-9 displays significant direct interstitial collagenase activity on native forms of collagen I and III reducing fibrogenesis [12,35-37]. In PHT it is not known whether the MMP-9+ macrophage subpopulation within the portal and periductal regions is specifically recruited to this location, or whether infiltrating or resident monocytes are stimulated to differentiate and express MMP-9 in the inflamed portal microenvironment [33].

Different levels of NO may have different effects on MMP-9 expression [38]. In chronic liver injury, excessive MMP-9 activity induced by PHT shear stress may have the potential to induce initial liver injury [12].

Consistent with the current reports, we found in the present study in PHT patients a decreased level of serum MMP-9 correlated with the high nitro-oxidative stress. Furthermore, in addition to their ability to degrade extracellular matrix, MMP process several non-matrix substrates such as growth factors and cytokines [33]. Consequently, data obtained indicate that this might be a mechanism that induced a close negative correlation between the changes in the levels of MMP-9 and VEGF in NCPT patients.

In conclusion, our data suggest that in PHT systemic excessive NO release and associated oxidative stress induce together nitro-oxidative stress and VEGF increase, and these changes were more severe in NCPT than in CPHT patients. In the NCPHT group the reduction of the serum MMP-9 level may be a mechanism of higher nitro-oxidative stress and the angiogenetic factor VEGF.

References
1. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715–1728.
2. Sarin SK, Kumar A, Chawla YK, Bajjal SY, Dhiman RK, Jafari W, et al. Noncirrhotic portal fibrosis idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007;1:398–413.
3. Khanna R, Sarin SK. Non-cirrhotic portal hypertension – diagnosis and management. J Hepatol. 2014;60:421–441.
4. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int. 2012;32(2):199-213.
5. Kajita M, Murata T, Horiguchi K, Iizuka M, Hori M, Ozaki H. iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats. Am J Physiol Heart Circ Physiol. 2011;300:H1021-H1031.
6. Schouten JN, Van der Ende ME, Koëter T, Rossing HH, Komuta M, Verheij J, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther. 2012;36:875–885.
7. Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol. 2013;9(11):1707-1717.
8. Malyshiev E, Tazi KA, Moreau R, Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol. 2007;22:2195-2201.
9. Sastre E, Balfagón G, Revuelta-López E, Aller MÁ, Nava MP, Arias J, et al. Effect of short- and long-term portal hypertension on adrenergic, nitrergic and sensory functioning in rat mesenteric artery. Clin Sci (Lond). 2012;122:337-348.
10. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620.
11. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Grossmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;290:G980-G987.
12. Ohashi N, Hori T, Chen F, Jermanus S, Nakao A, Uemoto S, et al. Matrix metalloproteinase-9 in the initial injury after hepatectomy in mice. World J Gastroenterol. 2013;19(20):3027-3042.
13. Muti LA, Sparcchenzi Z, Iobagiu S, Acalovschi M. The etiology of non-cirrhotic portal hypertension. A study of 105 consecutive patients. Clujul Medical. 2012;85:2200-2206.
14. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5:62–71.
15. Ghasemi A, Hedayati M, Biabani H. Protein precipitation methods evaluated for determination of serum nitric oxide end products by the Griess assay. J Med Sci Res. 2007;2:29–32.
16. Khan J, Brennand DM, Bradley N, Gao B, Bruckdorfer R, Jacobs M. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J. 1998;330:795–801.
17. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103-1111.
18. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112-119.
19. Harma M, Harma M, Erel O. Increased oxidative stress in patients with hydatidiform mole. Swiss Med Wkly. 2003;133:563-566.
20. Cantez MS, Gerenli N, Ertekin V, Güllüoğlu M, Durmaz O. Hepatoportal sclerosis in childhood: descriptive analysis of 12 patients. J Korean Med Sci. 2013;28:1507-1511.
21. Vujanac A, Jakovljevic V, Djordjevic D, Zivkovic V, Stojkovic M, Celikovic D, et al. Nitroglycerine effects on portal vein mechanics and oxidative stress in portal hypertension. World J Gastroenterol. 2012;18(4):331-339.
22. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2010;2(6):208-220.
23. Marques C, Licks F, Zattoni I, Borges B, de Souza LE, Marroni CA, et al. Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy. World J Gastroenterol. 2013;19(28):4464-4474.
24. Ahmed AF, El-Maraghy NN, Abdel Ghaney RH, Elshazly SM. Therapeutic effect of captopril, pentoxifylline, and Cordyceps sinensis in pre-hepatic portal hypertensive rats. Saudi J Gastroenterol. 2012;18:182-187.
25. Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014; 20(10):2555-2563.
26. Hong WK, Shim KY, Baik SK, Kim MY, Cho MY, Jang YO, et al. Relationship between tetrahidrobiopterin and portal hypertension in patients with chronic liver disease. J Korean Med Sci. 2014;29:392-399.
27. Basak S, Hoffmann A. Crosstalk via the NF-kappaB signaling system. Cytokine Growth Factor Rev. 2008;19:187-197.
28. Horii T, Uemoto S, Chen F, Gardner LB, Baine AM, Hata T, et al. Oxidative stress and extracellular matrices after heptectomy and liver transplantation in rats. World J Hepatol. 2014;6(2):72-84.
29. Iwakiri Y. Endothelial dysfunction in the regulation of portal hypertension. Liver Int. 2012;32(2):199–213.
30. Huang HC, Haq O, Utsumi T, Sethanese S, Abraldes JG, Groszmann RJ, et al. Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. J Cell Mol Med. 2012;16(5):1125–1133.
31. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008;45(1):18-31.
32. Vaillant B, Chiaromonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol. 2001;167(12):7017-26.
33. Gadd V, Melino M, Roy S, Horsfall L, O’Rourke P, Williams MR, et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver Int. 2013;33:569–579.
34. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(46):E3186-3195.
35. Jiao JJ, Sastre D, Fiel MI, Lee UE, Ghiassi-Nejad Z, Ginhoux F, et al. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology. 2012;55(1):244–255.
36. Tacke F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S27.
37. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (mmp)-3 activates mmp-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 2011;31:e35–44.